ClinicalTrials.gg
Not yet recruitingNCT07637279PCAPS2Updated Jun 9, 2026

Patient Controlled Propofol Sedation Versus Standard Sedation in Advanced Therapeutic Colonoscopy With a Focus on Patient Satisfaction

A Phase 4 interventional study of Patient controlled analgesia and Standard medical treatment in Colo-rectal Polyps, sponsored by Karolinska Institutet. Not yet recruiting at 2 sites in Sweden. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Karolinska Institutet · Phase 4, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Patient Satisfaction with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Patient Satisfaction · Sweden.

Started
2026
the only one that year
Phase 4
3 of 18
2 open now
Registered
18th of 18
by date
Lead sponsor
7 of 18
Karolinska Institutet

Among the 18 studies in Patient Satisfaction with a site in Sweden, this one is the only one that started in 2026, is one of 3 in phase 4, and was the 18th registered.

Patient Satisfaction

882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.

Browse Patient Satisfaction studies →

Open to participants now

5 of the 18 studies in Patient Satisfaction with a site in Sweden are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Patient Satisfaction with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if patient administered propofol sedation results in superior patient satisfaction compared to standard conscious sedation in advanced therapeutic endoscopy.

  • Does self administration of the sedative propofol increase patient satisfaction? Researchers will compare patient administered propofol sedation (where the patient administers propofol by pushing a button) with standard conscious sedation

Participants will:

  • Be randomized to either sedation route.
  • Answer a preendoscopy questioneere and a postendoscopy questioneere 1 hour after the examination as well as one week after the examination.
03

Conditions studied

  • Colo-rectal Polyps

Browse trials for

Keywords

  • Colonoscopy
  • Endoscopic submucosal dissection
  • Patient satisfaction
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for elective diagnostic colonoscopy in propofol sedation
  • Able to understand the study information and provide inform consent
  • Able to understand and use the patient-controlled sedation device
  • Able to complete study questioneeres

Exclusion criteria

Exclusion Criteria:

  • ASA >=III
  • Known or to propofol or any in the formulation.
  • Pregnancy or breastfeeding.
  • Inability to provide valid
  • Cognitive impairment, severe psychiatric illness, or other condition limiting reliable participation or questionnaire completion.
  • Inability to understand study procedures or insufficient language proficiency without available validated study support.
  • History of serious adverse reaction or complication related to sedation or anesthesia.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Patient controlled propofol sedation

    Patient controlled propofol sedation. By pushing a button the patient will be administred a bolusdose of propofol 5 mg intravenously. There is a lock-out function of max 8 administrations per minute, ie the maximum propofol dose per minute is 40 mg.

    Drug: Patient controlled analgesia

  • Active comparator
    Standard conscious sedation with midazolam and fentanyl

    Conscious sedation with midazolam and/or fentanyl administred by the endoscopy nurse. Midazolam will be given in doses of 1-2 mg intravenously. Fentanyl will be given, if needed, in doses of 0.25-0.5 mg intravenously

    Drug: Standard medical treatment

Interventions

  • DrugPatient controlled analgesia

    Patient controlled propofol sedation. 5 mg propofol iv per push. Max 8 pushes/minute

  • DrugStandard medical treatment

    Midazolam and/or fentanyl given intravenously as needed by endoscopy nurse

06

What researchers measure

Primary outcomes

  1. Patient satisfaction

    Patient satisfaction measured using Patient satisfaction with sedation index (PSSI), a validated Likert-scale questionnaire with 13 questions. Each question with 5 ranks (1-5). Minimum score 13, maximum score 65. Higher score indicates higher satisfaction.

    Time frame: One hour after the procedure and one week after the procedure

Secondary outcomes

  1. Recovery time

    Time before the patient can be discharged from the endoscopy unit.

    Time frame: <4 hours post examination

  2. Procedure duration

    Time to completion of the procedure (min)

    Time frame: Postprocedure

  3. Adverse events

    Any adverse events related to sedation within 30 days

    Time frame: 30 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in this study will be made available upon reasonable request. The shared data will include all variables necessary to reproduce the findings presented in the article. Data will be available beginning immediately following publication and will remain available for 5 years to researchers who provide a methodologically sound proposal.

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: Data will be available beginning immediately following publication and will remain available for 5 years to researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

Of 24 phase 4 interventional studies under Patient Satisfaction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 9, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jun 15, 2028
CompletionEst.
Nov 1, 2028
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07637279
Collaborators
Danderyd Hospital, Capio Sankt Görans Hospital
Responsible party
Richard Marsk (Associate professor, Karolinska Institutet) — Principal investigator
First posted
Jun 9, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jun 15, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jun 9, 2026

Study contacts

Richard E Marsk, MD, Docent
Contact
richard.marsk@ki.se
+46 8 123 71956
Richard E Marsk, MD, Docent
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion